

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., ... & Nukiwa, T. (2010). Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. *New England Journal of Medicine*, 362(25), 2380-2388.

Maestro, V. (2011). 9.2 Schrödinger. LLC, New York, NY.

Marx, G. M., Pavlakis, N., McCowatt, S., Boyle, F. M., Levi, J. A., Bell, D. R., ... & Wheeler, H. R. (2001). Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. *Journal of Neuro-oncology*, 54(1), 31-38.

Mathers, C. D., Fat, D. M., & Boerma, J. T. (2008). The global burden of disease: 2004 update. *World Health Organization*, 118:2702–2709.

McCarthy, M. J., Crowther, M., RF Bell, P., & Brindle, N. P. (1998). The endothelial receptor tyrosine kinase tie-1 is upregulated by hypoxia and vascular endothelial growth factor. *FEBS letters*, 423(3), 334-338.

Merchant, J. J., Kim, K., Mehta, M. P., Ripple, G. H., Larson, M. L., Brophy, D. J., ... & Schiller, J. H. (2000). Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non–small-cell lung cancer. *Clinical lung cancer*, 2(1), 48-52.

Mesri, M., Morales-Ruiz, M., Ackermann, E. J., Bennett, C. F., Pober, J. S., Sessa, W. C., & Altieri, D. C. (2001). Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. *The American journal of pathology*, 158(5), 1757-1765.

Meyer, N., & Penn, L. Z. (2008). Reflecting on 25 years with MYC. *Nature Reviews Cancer*, 8(12), 976-990.

Michael, M., Babic, B., Khokha, R., Tsao, M., Ho, J., Pintilie, M., ... & Shepherd, F. A. (1999). Expression and prognostic significance of metalloproteinases and